Drug Type Small molecule drug |
Synonyms (S)-8-((S)-5-chloro-6-fluoro-2-phenyl-2-((S)-pyrrolidin-2-yl)-2,3-dihydrobenzofuran-4-yl)-9-fluoro-N,2-dimethyl-1-oxo-1,2-dihydrobenzo[5,6][1,4]dioxino[2,3-d]pyridazine-7-carboxamide hydrochloride, ETS 006, ETS006 |
Target |
Mechanism TEAD inhibitors(TEA domain transcription factors inhibitors), YAP1 inhibitors(Yes1 associated transcriptional regulator inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhaseIND Approval |
First Approval Date- |
RegulationOrphan Drug (US) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | IND Approval | US | 19 Dec 2024 | |
Malignant Pleural Mesothelioma | Preclinical | CN | 22 Mar 2024 | |
Osteosarcoma | Preclinical | CN | 22 Mar 2024 | |
Squamous Cell Carcinoma of Head and Neck | Preclinical | CN | 22 Mar 2024 | |
Triple Negative Breast Cancer | Preclinical | CN | 22 Mar 2024 |